Compare JPMorgan Equity Premium Income ETF (JEPI) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Equity Premium Income ETF vs Tango Therapeutics Inc. — how do they compare? JPMorgan Equity Premium Income ETF trades at $56.77 (market cap $45.69B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: JPMorgan Equity Premium Income ETF is far larger — about 12.2× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Equity Premium Income ETF for 58 Days and Tango Therapeutics Inc. for 0 Days on average.
| JEPI | TNGX | |
|---|---|---|
Market Cap | $45.69B | $3.75B |
Volume | 3,633,306 | 9,619,106 |
Sector | Income / Options Overlay | Health |
52-Week High | $59.88 | $32.90 |
52-Week Low | $55.29 | $7.50 |
Typical Hold Time | 58 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPI trades at $56.93 with minimal daily movement (-0.05%) and maintains a bullish technical outlook based on moving averages. The ETF continues its consistent dividend distribution strategy with recent payments of $0.37 per share. Technical indicators show mixed signals with RSI levels ranging from neutral to overbought, while the overall trend remains positive.
The covered-call strategy provides income stability but may limit upside during strong market rallies. Recent media coverage highlights JEPI's role in retirement income strategies, though investors should consider tax implications and income limitations compared to pure equity exposure.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
